{
  "ticker": "JNJ",
  "key": "JNJ_Q4_2025",
  "year": 2025,
  "quarter": 4,
  "verified_at": "2026-02-13T12:10:17.504726",
  "claims_with_verdicts": [
    {
      "claim": {
        "qualifiers": [
          "over"
        ],
        "quote_end_char": 3746,
        "quote_start_char": 3615,
        "metric_type": "other",
        "period": "FY 2025",
        "claimed_value": 32,
        "quote_text": "In 2025, we invested over $32 billion in R&D and M&A, including the acquisitions of Intracellular Therapies and Halda Therapeutics.",
        "speaker_role": "ceo",
        "confidence": 1,
        "gaap_classification": "unknown",
        "speaker": "Joaquin Duato",
        "unit": "dollars",
        "claimed_value_raw": "$32 billion",
        "metric_context": "Total",
        "claim_type": "absolute",
        "is_approximate": false,
        "claim_id": "claim_001",
        "scale": "billions"
      },
      "verification": {
        "claim_id": "claim_001",
        "claimed_value": 32,
        "actual_value": null,
        "difference": null,
        "difference_pct": null,
        "tolerance_used": null,
        "computation_detail": null,
        "computation_steps": [],
        "financial_facts_used": [],
        "evidence_source": null,
        "flags": [],
        "misleading_flags": [],
        "misleading_reasons": [],
        "explanation": "Cannot verify: full_year",
        "verdict": "unverifiable"
      }
    },
    {
      "claim": {
        "scale": "ones",
        "period": "FY 2025",
        "quote_end_char": null,
        "gaap_classification": "gaap",
        "claim_id": "claim_002",
        "qualifiers": [],
        "claimed_value_raw": "5.3%",
        "metric_context": "Total",
        "speaker_role": "ceo",
        "unit": "percent",
        "quote_text": "Over the full year, we delivered 5.3% operational sales growth.",
        "metric_type": "revenue",
        "speaker": "Joaquin Duato",
        "claimed_value": 5.3,
        "quote_start_char": null,
        "comparison_period": "FY 2024",
        "is_approximate": false,
        "confidence": 1,
        "claim_type": "yoy_growth"
      },
      "verification": {
        "claim_id": "claim_002",
        "claimed_value": 5.3,
        "actual_value": null,
        "difference": null,
        "difference_pct": null,
        "tolerance_used": null,
        "computation_detail": null,
        "computation_steps": [],
        "financial_facts_used": [],
        "evidence_source": null,
        "flags": [],
        "misleading_flags": [],
        "misleading_reasons": [],
        "explanation": "Cannot verify: full_year",
        "verdict": "unverifiable"
      }
    },
    {
      "claim": {
        "speaker": "Joaquin Duato",
        "quote_text": "In innovative medicine, we reported operational sales growth for the year of 5.3%.",
        "unit": "percent",
        "speaker_role": "ceo",
        "quote_start_char": 4957,
        "quote_end_char": 5039,
        "scale": "ones",
        "claimed_value": 5.3,
        "is_approximate": false,
        "confidence": 1,
        "comparison_period": "FY 2024",
        "metric_context": "Innovative Medicine",
        "claim_type": "yoy_growth",
        "qualifiers": [],
        "gaap_classification": "gaap",
        "period": "FY 2025",
        "metric_type": "revenue",
        "claim_id": "claim_003",
        "claimed_value_raw": "5.3%"
      },
      "verification": {
        "claim_id": "claim_003",
        "claimed_value": 5.3,
        "actual_value": null,
        "difference": null,
        "difference_pct": null,
        "tolerance_used": null,
        "computation_detail": null,
        "computation_steps": [],
        "financial_facts_used": [],
        "evidence_source": null,
        "flags": [],
        "misleading_flags": [],
        "misleading_reasons": [],
        "explanation": "Cannot verify: full_year",
        "verdict": "unverifiable"
      }
    },
    {
      "claim": {
        "gaap_classification": "gaap",
        "quote_end_char": 5166,
        "speaker": "Joaquin Duato",
        "qualifiers": [
          "exceeded",
          "for the first time"
        ],
        "claim_type": "absolute",
        "confidence": 1,
        "quote_start_char": 5040,
        "is_approximate": false,
        "scale": "billions",
        "claimed_value": 60,
        "metric_context": "Pharmaceutical",
        "claimed_value_raw": "$60 billion",
        "metric_type": "revenue",
        "claim_id": "claim_004",
        "unit": "dollars",
        "speaker_role": "ceo",
        "quote_text": "Full-year sales for our Pharmaceutical business exceeded $60 billion for the first time, with 13 brands growing double digits.",
        "period": "FY 2025"
      },
      "verification": {
        "claim_id": "claim_004",
        "claimed_value": 60,
        "actual_value": null,
        "difference": null,
        "difference_pct": null,
        "tolerance_used": null,
        "computation_detail": null,
        "computation_steps": [],
        "financial_facts_used": [],
        "evidence_source": null,
        "flags": [],
        "misleading_flags": [],
        "misleading_reasons": [],
        "explanation": "Cannot verify: full_year",
        "verdict": "unverifiable"
      }
    },
    {
      "claim": {
        "claimed_value_raw": "21%",
        "comparison_period": "FY 2024",
        "scale": "ones",
        "claimed_value": 21,
        "metric_type": "revenue",
        "claim_id": "claim_005",
        "period": "FY 2025",
        "speaker": "Joaquin Duato",
        "qualifiers": [],
        "quote_start_char": 5719,
        "gaap_classification": "gaap",
        "is_approximate": false,
        "quote_text": "In 2025, we delivered 21% operational sales growth, and we expect to exceed $50 billion in annual sales by 2030.",
        "metric_context": "Oncology",
        "claim_type": "yoy_growth",
        "unit": "percent",
        "speaker_role": "ceo",
        "quote_end_char": 5831,
        "confidence": 1
      },
      "verification": {
        "claim_id": "claim_005",
        "claimed_value": 21,
        "actual_value": null,
        "difference": null,
        "difference_pct": null,
        "tolerance_used": null,
        "computation_detail": null,
        "computation_steps": [],
        "financial_facts_used": [],
        "evidence_source": null,
        "flags": [],
        "misleading_flags": [],
        "misleading_reasons": [],
        "explanation": "Cannot verify: full_year",
        "verdict": "unverifiable"
      }
    },
    {
      "claim": {
        "quote_text": "With annual sales over $14 billion, DARZALEX grew an impressive 22% across the full year.",
        "claim_id": "claim_007",
        "scale": "billions",
        "is_approximate": false,
        "metric_type": "revenue",
        "gaap_classification": "gaap",
        "quote_start_char": 6152,
        "unit": "dollars",
        "speaker": "Joaquin Duato",
        "qualifiers": [
          "over"
        ],
        "claimed_value": 14,
        "speaker_role": "ceo",
        "confidence": 1,
        "period": "FY 2025",
        "claimed_value_raw": "$14 billion",
        "quote_end_char": 6241,
        "metric_context": "DARZALEX",
        "claim_type": "absolute"
      },
      "verification": {
        "claim_id": "claim_007",
        "claimed_value": 14,
        "actual_value": null,
        "difference": null,
        "difference_pct": null,
        "tolerance_used": null,
        "computation_detail": null,
        "computation_steps": [],
        "financial_facts_used": [],
        "evidence_source": null,
        "flags": [],
        "misleading_flags": [],
        "misleading_reasons": [],
        "explanation": "Cannot verify: full_year",
        "verdict": "unverifiable"
      }
    },
    {
      "claim": {
        "claim_type": "absolute",
        "unit": "dollars",
        "period": "FY 2025",
        "gaap_classification": "gaap",
        "metric_type": "revenue",
        "metric_context": "Tremfya",
        "quote_start_char": 8137,
        "qualifiers": [
          "more than",
          "for the first time"
        ],
        "confidence": 1,
        "claim_id": "claim_009",
        "quote_text": "And with global full-year sales of Tremfya accelerating to more than $5 billion for the first time, we're increasingly confident that Tremfya will exceed $10 billion in peak year sales.",
        "speaker": "Joaquin Duato",
        "scale": "billions",
        "claimed_value": 5,
        "is_approximate": false,
        "speaker_role": "ceo",
        "quote_end_char": 8322,
        "claimed_value_raw": "$5 billion"
      },
      "verification": {
        "claim_id": "claim_009",
        "claimed_value": 5,
        "actual_value": null,
        "difference": null,
        "difference_pct": null,
        "tolerance_used": null,
        "computation_detail": null,
        "computation_steps": [],
        "financial_facts_used": [],
        "evidence_source": null,
        "flags": [],
        "misleading_flags": [],
        "misleading_reasons": [],
        "explanation": "Cannot verify: full_year",
        "verdict": "unverifiable"
      }
    },
    {
      "claim": {
        "quote_end_char": 8823,
        "comparison_period": "FY 2024",
        "qualifiers": [],
        "metric_type": "revenue",
        "confidence": 1,
        "unit": "percent",
        "claim_id": "claim_010",
        "claimed_value": 10,
        "speaker_role": "ceo",
        "claimed_value_raw": "10%",
        "quote_text": "Turning to neuroscience, where 2025 operational sales grew 10%.",
        "claim_type": "yoy_growth",
        "is_approximate": false,
        "quote_start_char": 8760,
        "scale": "ones",
        "period": "FY 2025",
        "metric_context": "Neuroscience",
        "speaker": "Joaquin Duato",
        "gaap_classification": "gaap"
      },
      "verification": {
        "claim_id": "claim_010",
        "claimed_value": 10,
        "actual_value": null,
        "difference": null,
        "difference_pct": null,
        "tolerance_used": null,
        "computation_detail": null,
        "computation_steps": [],
        "financial_facts_used": [],
        "evidence_source": null,
        "flags": [],
        "misleading_flags": [],
        "misleading_reasons": [],
        "explanation": "Cannot verify: full_year",
        "verdict": "unverifiable"
      }
    },
    {
      "claim": {
        "gaap_classification": "gaap",
        "quote_text": "Spravato continues its strong trajectory with 57% growth in the year, with more than two hundred thousand patients now treated worldwide.",
        "quote_end_char": 8962,
        "claim_id": "claim_011,claim_type:",
        "comparison_period": "FY 2024",
        "unit": "percent",
        "claimed_value": 57,
        "speaker": "Joaquin Duato",
        "qualifiers": [],
        "speaker_role": "ceo",
        "claimed_value_raw": "57%",
        "period": "FY 2025",
        "scale": "ones",
        "quote_start_char": 8825,
        "metric_context": "Spravato",
        "confidence": 1,
        "claim_type": "yoy_growth",
        "is_approximate": false,
        "metric_type": "revenue"
      },
      "verification": {
        "claim_id": "claim_011,claim_type:",
        "claimed_value": 57,
        "actual_value": null,
        "difference": null,
        "difference_pct": null,
        "tolerance_used": null,
        "computation_detail": null,
        "computation_steps": [],
        "financial_facts_used": [],
        "evidence_source": null,
        "flags": [],
        "misleading_flags": [],
        "misleading_reasons": [],
        "explanation": "Cannot verify: full_year",
        "verdict": "unverifiable"
      }
    },
    {
      "claim": {
        "metric_context": "MedTech",
        "period": "FY 2025",
        "speaker_role": "ceo",
        "quote_text": "Now turning to MedTech, where operational sales for the year grew 5.4%.",
        "scale": "ones",
        "unit": "percent",
        "quote_start_char": 9159,
        "quote_end_char": 9230,
        "comparison_period": "FY 2024",
        "claim_type": "yoy_growth",
        "metric_type": "revenue",
        "gaap_classification": "gaap",
        "is_approximate": false,
        "confidence": 1,
        "speaker": "Joaquin Duato",
        "claim_id": "claim_012",
        "claimed_value_raw": "5.4%",
        "qualifiers": [],
        "claimed_value": 5.4
      },
      "verification": {
        "claim_id": "claim_012",
        "claimed_value": 5.4,
        "actual_value": null,
        "difference": null,
        "difference_pct": null,
        "tolerance_used": null,
        "computation_detail": null,
        "computation_steps": [],
        "financial_facts_used": [],
        "evidence_source": null,
        "flags": [],
        "misleading_flags": [],
        "misleading_reasons": [],
        "explanation": "Cannot verify: full_year",
        "verdict": "unverifiable"
      }
    },
    {
      "claim": {
        "quote_text": "In 2025, we delivered nearly $4 billion in sales, with strong performance in cardiovascular and accelerating momentum across surgery and vision.",
        "gaap_classification": "gaap",
        "speaker_role": "ceo",
        "qualifiers": [
          "nearly"
        ],
        "is_approximate": true,
        "confidence": 1,
        "claim_type": "absolute",
        "quote_end_char": 9375,
        "unit": "dollars",
        "metric_context": "MedTech",
        "speaker": "Joaquin Duato",
        "claim_id": "claim_013",
        "period": "FY 2025",
        "scale": "billions",
        "claimed_value": 4,
        "claimed_value_raw": "$4 billion",
        "quote_start_char": 9231,
        "metric_type": "revenue"
      },
      "verification": {
        "claim_id": "claim_013",
        "claimed_value": 4,
        "actual_value": null,
        "difference": null,
        "difference_pct": null,
        "tolerance_used": null,
        "computation_detail": null,
        "computation_steps": [],
        "financial_facts_used": [],
        "evidence_source": null,
        "flags": [],
        "misleading_flags": [],
        "misleading_reasons": [],
        "explanation": "Cannot verify: full_year",
        "verdict": "unverifiable"
      }
    },
    {
      "claim": {
        "confidence": 1,
        "scale": "ones",
        "metric_context": "Cardiovascular",
        "claim_id": "claim_014",
        "speaker_role": "ceo",
        "gaap_classification": "gaap",
        "quote_end_char": 9732,
        "is_approximate": false,
        "comparison_period": "FY 2024",
        "quote_text": "Johnson & Johnson today is a leader in three cardiovascular segments, with the portfolio delivering 15% operational sales growth in the year.",
        "unit": "percent",
        "claimed_value": 15,
        "claimed_value_raw": "15%",
        "speaker": "Joaquin Duato",
        "metric_type": "revenue",
        "qualifiers": [],
        "claim_type": "yoy_growth",
        "period": "FY 2025",
        "quote_start_char": 9591
      },
      "verification": {
        "claim_id": "claim_014",
        "claimed_value": 15,
        "actual_value": null,
        "difference": null,
        "difference_pct": null,
        "tolerance_used": null,
        "computation_detail": null,
        "computation_steps": [],
        "financial_facts_used": [],
        "evidence_source": null,
        "flags": [],
        "misleading_flags": [],
        "misleading_reasons": [],
        "explanation": "Cannot verify: full_year",
        "verdict": "unverifiable"
      }
    },
    {
      "claim": {
        "qualifiers": [],
        "speaker": "Joaquin Duato",
        "is_approximate": false,
        "claim_id": "claim_015",
        "claim_type": "yoy_growth",
        "claimed_value_raw": "5.3%",
        "claimed_value": 5.3,
        "unit": "percent",
        "quote_text": "And finally, vision, which delivered robust annual operational sales growth of 5.3% with particularly strong momentum in surgical vision.",
        "confidence": 1,
        "scale": "ones",
        "quote_end_char": 11392,
        "comparison_period": "FY 2024",
        "quote_start_char": 11255,
        "metric_context": "Vision",
        "metric_type": "revenue",
        "gaap_classification": "gaap",
        "speaker_role": "ceo",
        "period": "FY 2025"
      },
      "verification": {
        "claim_id": "claim_015",
        "claimed_value": 5.3,
        "actual_value": null,
        "difference": null,
        "difference_pct": null,
        "tolerance_used": null,
        "computation_detail": null,
        "computation_steps": [],
        "financial_facts_used": [],
        "evidence_source": null,
        "flags": [],
        "misleading_flags": [],
        "misleading_reasons": [],
        "explanation": "Cannot verify: full_year",
        "verdict": "unverifiable"
      }
    },
    {
      "claim": {
        "confidence": 1,
        "quote_text": "Starting with Q4 2025 sales results. Worldwide sales were $24.6 billion for the quarter.",
        "quote_end_char": 12320,
        "qualifiers": [],
        "unit": "dollars",
        "claim_id": "claim_016",
        "speaker_role": "management",
        "metric_type": "revenue",
        "claimed_value_raw": "$24.6 billion",
        "scale": "billions",
        "metric_context": "Total",
        "is_approximate": false,
        "claim_type": "absolute",
        "quote_start_char": 12232,
        "period": "Q4 2025",
        "gaap_classification": "gaap",
        "claimed_value": 24.6,
        "speaker": "Darren Snellgrove"
      },
      "verification": {
        "claim_id": "claim_016",
        "claimed_value": 24.6,
        "actual_value": 24564000000,
        "difference": 36000000.0,
        "difference_pct": 0.14655593551538837,
        "tolerance_used": 0.005,
        "computation_detail": "Claimed 24,600,000,000.00 vs Actual 24,564,000,000.00. Diff: 0.15% (threshold: 0.5%)",
        "computation_steps": [
          {
            "step": "Absolute comparison",
            "formula": "|24,600,000,000.00 - 24,564,000,000.00| / |24,564,000,000.00|",
            "result": 0.0014655593551538837,
            "threshold": 0.005
          }
        ],
        "financial_facts_used": [
          {
            "field": "revenue",
            "fy": 2025,
            "fq": 4,
            "value": 24564000000
          }
        ],
        "evidence_source": "fmp",
        "flags": [],
        "misleading_flags": [],
        "misleading_reasons": [],
        "explanation": "Verified: claimed 24,600,000,000.00 vs actual 24,564,000,000.00 from fmp.",
        "verdict": "verified"
      }
    },
    {
      "claim": {
        "claim_type": "yoy_growth",
        "gaap_classification": "gaap",
        "claimed_value": 7.1,
        "is_approximate": false,
        "quote_end_char": 12404,
        "speaker": "Darren Snellgrove",
        "comparison_period": "Q4 2024",
        "confidence": 1,
        "quote_start_char": 12322,
        "claim_id": "claim_017",
        "scale": "ones",
        "qualifiers": [],
        "metric_context": "Total",
        "claimed_value_raw": "7.1%",
        "period": "Q4 2025",
        "unit": "percent",
        "metric_type": "revenue",
        "speaker_role": "management",
        "quote_text": "Sales increased 7.1% despite an approximate 650 basis point headwind from STELARA."
      },
      "verification": {
        "claim_id": "claim_017",
        "claimed_value": 7.1,
        "actual_value": 24564000000,
        "difference": -1.9763765541740685,
        "difference_pct": 1.9763765541740685,
        "tolerance_used": 1.0,
        "computation_detail": "Claimed 7.1% YoY growth. Actual: (24,564,000,000 - 22,520,000,000) / 22,520,000,000 = 9.08%. Diff: 1.98 pp (threshold: 1.0 pp)",
        "computation_steps": [
          {
            "step": "YoY growth",
            "formula": "(24,564,000,000 - 22,520,000,000) / |22,520,000,000| * 100",
            "result": 9.076376554174068,
            "claimed": 7.1,
            "difference_pp": -1.9763765541740685
          }
        ],
        "financial_facts_used": [
          {
            "field": "revenue",
            "fy": 2025,
            "fq": 4,
            "value": 24564000000
          },
          {
            "field": "revenue",
            "fy": 2024,
            "fq": 4,
            "value": 22520000000
          }
        ],
        "evidence_source": "fmp (current), fmp (prior)",
        "flags": [],
        "misleading_flags": [],
        "misleading_reasons": [],
        "explanation": "Growth claim: 7.1% claimed. Computed from Q4 2025 (24,564,000,000) vs Q4 2024 (22,520,000,000) = 9.08% actual.",
        "verdict": "close_match"
      }
    },
    {
      "claim": {
        "period": "Q4 2025",
        "quote_end_char": 12746,
        "qualifiers": [],
        "claim_id": "claim_018",
        "quote_text": "For the quarter, net earnings were $5.1 billion, and diluted earnings per share was $2.1 versus $1.41 a year ago.",
        "metric_context": "Total",
        "speaker": "Darren Snellgrove",
        "speaker_role": "management",
        "scale": "billions",
        "claim_type": "absolute",
        "confidence": 1,
        "unit": "dollars",
        "gaap_classification": "gaap",
        "is_approximate": false,
        "metric_type": "net_income",
        "claimed_value_raw": "$5.1 billion",
        "quote_start_char": 12633,
        "claimed_value": 5.1
      },
      "verification": {
        "claim_id": "claim_018",
        "claimed_value": 5.1,
        "actual_value": 5116000000,
        "difference": -16000000.0,
        "difference_pct": 0.3127443315089914,
        "tolerance_used": 0.01,
        "computation_detail": "Claimed 5,100,000,000.00 vs Actual 5,116,000,000.00. Diff: 0.31% (threshold: 1.0%)",
        "computation_steps": [
          {
            "step": "Absolute comparison",
            "formula": "|5,100,000,000.00 - 5,116,000,000.00| / |5,116,000,000.00|",
            "result": 0.003127443315089914,
            "threshold": 0.01
          }
        ],
        "financial_facts_used": [
          {
            "field": "net_income",
            "fy": 2025,
            "fq": 4,
            "value": 5116000000
          }
        ],
        "evidence_source": "fmp",
        "flags": [],
        "misleading_flags": [],
        "misleading_reasons": [],
        "explanation": "Verified: claimed 5,100,000,000.00 vs actual 5,116,000,000.00 from fmp.",
        "verdict": "verified"
      }
    },
    {
      "claim": {
        "qualifiers": [],
        "metric_type": "eps_diluted",
        "scale": null,
        "claim_id": "claim_019",
        "speaker": "Darren Snellgrove",
        "confidence": 1,
        "claimed_value_raw": "$2.1",
        "is_approximate": false,
        "unit": "per_share",
        "quote_text": "For the quarter, net earnings were $5.1 billion, and diluted earnings per share was $2.1 versus $1.41 a year ago.",
        "claimed_value": 2.1,
        "quote_start_char": 12633,
        "quote_end_char": 12746,
        "speaker_role": "management",
        "gaap_classification": "gaap",
        "metric_context": "Total",
        "period": "Q4 2025",
        "claim_type": "absolute"
      },
      "verification": {
        "claim_id": "claim_019",
        "claimed_value": 2.1,
        "actual_value": 2.1,
        "difference": 0.0,
        "difference_pct": 0.0,
        "tolerance_used": 0.015,
        "computation_detail": "EPS: claimed $2.10 vs actual $2.10. Diff $0.000 within $0.015 tolerance.",
        "computation_steps": [
          {
            "step": "EPS absolute comparison",
            "formula": "|2.10 - 2.10| = 0.000",
            "result": 0.0,
            "threshold": 0.015
          }
        ],
        "financial_facts_used": [
          {
            "field": "eps_diluted",
            "fy": 2025,
            "fq": 4,
            "value": 2.1
          }
        ],
        "evidence_source": "fmp",
        "flags": [],
        "misleading_flags": [],
        "misleading_reasons": [],
        "explanation": "Verified: claimed $2.10 matches actual $2.10.",
        "verdict": "verified"
      }
    },
    {
      "claim": {
        "qualifiers": [
          "Adjusted"
        ],
        "claimed_value_raw": "$6 billion",
        "period": "Q4 2025",
        "quote_end_char": 12904,
        "quote_start_char": 12748,
        "claim_type": "absolute",
        "speaker": "Darren Snellgrove",
        "metric_context": "Total",
        "scale": "billions",
        "speaker_role": "management",
        "quote_text": "Adjusted net earnings for the quarter were $6 billion, and adjusted diluted earnings per share of $2.46, representing an increase of 21.5% compared to 2024.",
        "confidence": 1,
        "unit": "dollars",
        "claim_id": "claim_020",
        "is_approximate": false,
        "claimed_value": 6,
        "metric_type": "net_income",
        "gaap_classification": "non_gaap"
      },
      "verification": {
        "claim_id": "claim_020",
        "claimed_value": 6,
        "actual_value": null,
        "difference": null,
        "difference_pct": null,
        "tolerance_used": null,
        "computation_detail": null,
        "computation_steps": [],
        "financial_facts_used": [],
        "evidence_source": null,
        "flags": [
          "non_gaap_claim"
        ],
        "misleading_flags": [],
        "misleading_reasons": [],
        "explanation": "This claim references a non-GAAP metric. Our data sources contain GAAP figures only. Non-GAAP metrics exclude items like stock-based compensation or restructuring charges.",
        "verdict": "unverifiable"
      }
    },
    {
      "claim": {
        "speaker": "Darren Snellgrove",
        "metric_type": "eps_diluted",
        "metric_context": "Total",
        "gaap_classification": "non_gaap",
        "claimed_value_raw": "$2.46",
        "period": "Q4 2025",
        "quote_text": "Adjusted net earnings for the quarter were $6 billion, and adjusted diluted earnings per share of $2.46, representing an increase of 21.5% compared to 2024.",
        "confidence": 1,
        "qualifiers": [
          "adjusted"
        ],
        "claim_id": "claim_021",
        "scale": null,
        "speaker_role": "management",
        "quote_end_char": 12904,
        "claim_type": "absolute",
        "quote_start_char": 12748,
        "unit": "per_share",
        "is_approximate": false,
        "claimed_value": 2.46
      },
      "verification": {
        "claim_id": "claim_021",
        "claimed_value": 2.46,
        "actual_value": null,
        "difference": null,
        "difference_pct": null,
        "tolerance_used": null,
        "computation_detail": null,
        "computation_steps": [],
        "financial_facts_used": [],
        "evidence_source": null,
        "flags": [
          "non_gaap_claim"
        ],
        "misleading_flags": [],
        "misleading_reasons": [],
        "explanation": "This claim references a non-GAAP metric. Our data sources contain GAAP figures only. Non-GAAP metrics exclude items like stock-based compensation or restructuring charges.",
        "verdict": "unverifiable"
      }
    },
    {
      "claim": {
        "claim_id": "claim_022",
        "claimed_value": 94.2,
        "period": "FY 2025",
        "metric_type": "revenue",
        "unit": "dollars",
        "quote_start_char": 13071,
        "is_approximate": false,
        "confidence": 1,
        "claim_type": "absolute",
        "qualifiers": [],
        "quote_end_char": 13130,
        "scale": "billions",
        "metric_context": "Total",
        "quote_text": "For the full year 2025, worldwide sales were $94.2 billion.",
        "claimed_value_raw": "$94.2 billion",
        "speaker_role": "management",
        "speaker": "Darren Snellgrove",
        "gaap_classification": "gaap"
      },
      "verification": {
        "claim_id": "claim_022",
        "claimed_value": 94.2,
        "actual_value": null,
        "difference": null,
        "difference_pct": null,
        "tolerance_used": null,
        "computation_detail": null,
        "computation_steps": [],
        "financial_facts_used": [],
        "evidence_source": null,
        "flags": [],
        "misleading_flags": [],
        "misleading_reasons": [],
        "explanation": "Cannot verify: full_year",
        "verdict": "unverifiable"
      }
    },
    {
      "claim": {
        "speaker": "Darren Snellgrove",
        "claimed_value_raw": "$10.79",
        "metric_context": "Total",
        "claim_id": "claim_023",
        "qualifiers": [
          "adjusted"
        ],
        "period": "FY 2025",
        "unit": "per_share",
        "speaker_role": "management",
        "quote_start_char": 13857,
        "gaap_classification": "non_gaap",
        "confidence": 1,
        "claim_type": "absolute",
        "metric_type": "eps_diluted",
        "quote_end_char": 14031,
        "quote_text": "Full-year 2025 adjusted net earnings were $26.2 billion, and adjusted diluted earnings per share was $10.79, both representing an increase of 8.1% compared to full year 2024.",
        "is_approximate": false,
        "scale": null,
        "claimed_value": 10.79
      },
      "verification": {
        "claim_id": "claim_023",
        "claimed_value": 10.79,
        "actual_value": null,
        "difference": null,
        "difference_pct": null,
        "tolerance_used": null,
        "computation_detail": null,
        "computation_steps": [],
        "financial_facts_used": [],
        "evidence_source": null,
        "flags": [
          "non_gaap_claim"
        ],
        "misleading_flags": [],
        "misleading_reasons": [],
        "explanation": "This claim references a non-GAAP metric. Our data sources contain GAAP figures only. Non-GAAP metrics exclude items like stock-based compensation or restructuring charges.",
        "verdict": "unverifiable"
      }
    },
    {
      "claim": {
        "confidence": 1,
        "scale": "billions",
        "claimed_value": 15.8,
        "is_approximate": false,
        "quote_end_char": 14434,
        "gaap_classification": "gaap",
        "period": "Q4 2025",
        "claim_id": "claim_025",
        "metric_context": "Innovative Medicine",
        "quote_start_char": 14216,
        "metric_type": "revenue",
        "claim_type": "absolute",
        "claimed_value_raw": "$15.8 billion",
        "speaker": "Darren Snellgrove",
        "speaker_role": "management",
        "qualifiers": [],
        "unit": "dollars",
        "quote_text": "Beginning with innovative medicine, worldwide sales of $15.8 billion increased 7.9% despite an approximate 1110 basis point headwind from STELARA, illustrating the continued strength of our key brands and new launches."
      },
      "verification": {
        "claim_id": "claim_025",
        "claimed_value": 15.8,
        "actual_value": null,
        "difference": null,
        "difference_pct": null,
        "tolerance_used": null,
        "computation_detail": null,
        "computation_steps": [],
        "financial_facts_used": [],
        "evidence_source": null,
        "flags": [
          "segment_claim"
        ],
        "misleading_flags": [],
        "misleading_reasons": [],
        "explanation": "This is a Innovative Medicine revenue claim. Our data only includes total company-level figures.",
        "verdict": "unverifiable"
      }
    },
    {
      "claim": {
        "confidence": 1,
        "quote_text": "Carvictee achieved sales of $555 million with growth of 63.2%, driven by share gains and site expansion.",
        "claimed_value_raw": "$555 million",
        "unit": "dollars",
        "claim_id": "claim_026",
        "claimed_value": 555,
        "quote_start_char": 14883,
        "metric_type": "revenue",
        "qualifiers": [],
        "metric_context": "Carvictee",
        "speaker_role": "management",
        "speaker": "Darren Snellgrove",
        "is_approximate": false,
        "claim_type": "absolute",
        "period": "Q4 2025",
        "gaap_classification": "gaap",
        "quote_end_char": 14987,
        "scale": "millions"
      },
      "verification": {
        "claim_id": "claim_026",
        "claimed_value": 555,
        "actual_value": null,
        "difference": null,
        "difference_pct": null,
        "tolerance_used": null,
        "computation_detail": null,
        "computation_steps": [],
        "financial_facts_used": [],
        "evidence_source": null,
        "flags": [
          "segment_claim"
        ],
        "misleading_flags": [],
        "misleading_reasons": [],
        "explanation": "This is a Carvictee revenue claim. Our data only includes total company-level figures.",
        "verdict": "unverifiable"
      }
    },
    {
      "claim": {
        "metric_context": "Ribrovant plus Lascluse",
        "metric_type": "revenue",
        "scale": "millions",
        "gaap_classification": "gaap",
        "is_approximate": false,
        "period": "Q4 2025",
        "qualifiers": [],
        "claimed_value_raw": "$216 million",
        "quote_text": "In lung cancer, Ribrovant plus Lascluse delivered sales of $216 million and growth of 76.5%, driven by continued launch uptake in all regions.",
        "quote_start_char": 15261,
        "claim_type": "absolute",
        "speaker_role": "management",
        "claim_id": "claim_027",
        "quote_end_char": 15403,
        "unit": "dollars",
        "speaker": "Darren Snellgrove",
        "confidence": 1,
        "claimed_value": 216
      },
      "verification": {
        "claim_id": "claim_027",
        "claimed_value": 216,
        "actual_value": null,
        "difference": null,
        "difference_pct": null,
        "tolerance_used": null,
        "computation_detail": null,
        "computation_steps": [],
        "financial_facts_used": [],
        "evidence_source": null,
        "flags": [
          "segment_claim"
        ],
        "misleading_flags": [],
        "misleading_reasons": [],
        "explanation": "This is a Ribrovant plus Lascluse revenue claim. Our data only includes total company-level figures.",
        "verdict": "unverifiable"
      }
    },
    {
      "claim": {
        "claimed_value_raw": "$8.8 billion",
        "claim_id": "claim_028",
        "claim_type": "absolute",
        "speaker": "Darren Snellgrove",
        "speaker_role": "management",
        "confidence": 1,
        "metric_context": "MedTech",
        "unit": "dollars",
        "quote_start_char": 16131,
        "scale": "billions",
        "metric_type": "revenue",
        "gaap_classification": "gaap",
        "qualifiers": [],
        "period": "Q4 2025",
        "is_approximate": false,
        "quote_end_char": 16351,
        "claimed_value": 8.8,
        "quote_text": "Now moving to medtech. Worldwide sales of $8.8 billion increased 5.8%, with growth of 6.6% in the US and 4.9% outside of the US, driven by strong performance in our three focus areas: cardiovascular, surgery, and vision."
      },
      "verification": {
        "claim_id": "claim_028",
        "claimed_value": 8.8,
        "actual_value": null,
        "difference": null,
        "difference_pct": null,
        "tolerance_used": null,
        "computation_detail": null,
        "computation_steps": [],
        "financial_facts_used": [],
        "evidence_source": null,
        "flags": [
          "segment_claim"
        ],
        "misleading_flags": [],
        "misleading_reasons": [],
        "explanation": "This is a MedTech revenue claim. Our data only includes total company-level figures.",
        "verdict": "unverifiable"
      }
    },
    {
      "claim": {
        "is_approximate": false,
        "claimed_value": 19.7,
        "metric_type": "free_cash_flow",
        "gaap_classification": "unknown",
        "quote_start_char": 22059,
        "quote_end_char": 22216,
        "scale": "billions",
        "qualifiers": [],
        "period": "FY 2025",
        "quote_text": "The company generated $19.7 billion of free cash flow during 2025, on par with 2024 despite increased capital investment in the US and the impact of tariffs.",
        "speaker_role": "cfo",
        "metric_context": "Total",
        "speaker": "Joe Wolk",
        "claim_id": "claim_029",
        "claimed_value_raw": "$19.7 billion",
        "claim_type": "absolute",
        "unit": "dollars",
        "confidence": 1
      },
      "verification": {
        "claim_id": "claim_029",
        "claimed_value": 19.7,
        "actual_value": null,
        "difference": null,
        "difference_pct": null,
        "tolerance_used": null,
        "computation_detail": null,
        "computation_steps": [],
        "financial_facts_used": [],
        "evidence_source": null,
        "flags": [],
        "misleading_flags": [],
        "misleading_reasons": [],
        "explanation": "Cannot verify: full_year",
        "verdict": "unverifiable"
      }
    },
    {
      "claim": {
        "metric_type": "revenue",
        "confidence": 1,
        "claim_type": "guidance",
        "speaker_role": "cfo",
        "period": "FY 2026",
        "claimed_value_raw": "5.7%",
        "scale": "ones",
        "quote_end_char": 22785,
        "claimed_value": 5.7,
        "speaker": "Joe Wolk",
        "is_approximate": false,
        "metric_context": "Total",
        "unit": "percent",
        "gaap_classification": "gaap",
        "qualifiers": [],
        "quote_text": "Turning now to guidance for the full year 2026. We anticipate operational sales growth in the range of 5.7% to 6.7% with a midpoint of $100 billion or 6.2%.",
        "quote_start_char": 22629,
        "claim_id": "claim_030"
      },
      "verification": {
        "claim_id": "claim_030",
        "claimed_value": 5.7,
        "actual_value": null,
        "difference": null,
        "difference_pct": null,
        "tolerance_used": null,
        "computation_detail": null,
        "computation_steps": [],
        "financial_facts_used": [],
        "evidence_source": null,
        "flags": [
          "guidance_claim"
        ],
        "misleading_flags": [],
        "misleading_reasons": [],
        "explanation": "Forward-looking guidance claims cannot be verified against historical data.",
        "verdict": "unverifiable"
      }
    },
    {
      "claim": {
        "metric_context": "Total",
        "claim_type": "guidance",
        "quote_end_char": 25428,
        "period": "FY 2026",
        "claim_id": "claim_032",
        "scale": null,
        "metric_type": "eps_diluted",
        "claimed_value_raw": "$11.53",
        "is_approximate": false,
        "quote_text": "As such, we expect reported adjusted earnings per share of $11.53 at the midpoint.",
        "gaap_classification": "non_gaap",
        "quote_start_char": 25346,
        "qualifiers": [
          "reported adjusted",
          "midpoint"
        ],
        "unit": "per_share",
        "speaker_role": "cfo",
        "speaker": "Joe Wolk",
        "claimed_value": 11.53,
        "confidence": 1
      },
      "verification": {
        "claim_id": "claim_032",
        "claimed_value": 11.53,
        "actual_value": null,
        "difference": null,
        "difference_pct": null,
        "tolerance_used": null,
        "computation_detail": null,
        "computation_steps": [],
        "financial_facts_used": [],
        "evidence_source": null,
        "flags": [
          "non_gaap_claim"
        ],
        "misleading_flags": [],
        "misleading_reasons": [],
        "explanation": "This claim references a non-GAAP metric. Our data sources contain GAAP figures only. Non-GAAP metrics exclude items like stock-based compensation or restructuring charges.",
        "verdict": "unverifiable"
      }
    }
  ],
  "summary": {
    "total": 28,
    "verified": 3,
    "close_match": 1,
    "mismatch": 0,
    "misleading": 0,
    "unverifiable": 24
  }
}